Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:41:58.041Z.
Calculation as of: 2026-10-06T13:41:58.041Z.
Quote observation: 2026-10-06T13:39:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1719e487edf1987d8b1f0a43ac2cfa0d2aa61af237e007c9f807b404ec58ada8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Citius Pharmaceuticals, Inc.
Market Cap
$14.44M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.76M
Price/OCF Ratio
26.23
TTM Avg
28.16
3Y Avg
28.16
5Y Avg
28.16
Market Cap
$13.78M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.33M
Price/OCF Ratio
N/A
TTM Avg
57.00
3Y Avg
57.00
5Y Avg
57.00
Market Cap
$15.35M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.57M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $14.44M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.76M | 26.23 | 28.16 | 28.16 | 28.16 |
| IN8bio, Inc. (INAB)vs › | $13.71M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.78M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.88M | N/A | 3.83 | 3.83 | 3.83 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.33M | N/A | 57.00 | 57.00 | 57.00 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.35M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.70M | N/A | 9.81 | 9.81 | 9.81 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.57M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.23M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
